Femasys Expands Global Patent Portfolio with New Blended Polymer Patents for FemBloc Permanent Birth Control

Femasys Inc. (NASDAQ: FEMY), a biomedical innovator focused on fertility and non-surgical permanent birth control solutions, announced on August 12, 2026, the issuance of new patents in the United States and several international jurisdictions. These patents cover the blended polymer component of FemBloc, the company’s first-of-its-kind non-surgical permanent birth control technology. The new intellectual property rights complement existing patents protecting FemBloc’s delivery system, thereby extending the product’s global patent coverage.

FemBloc is designed to provide a non-surgical alternative to permanent sterilization by placing a blended polymer into both fallopian tubes. This polymer safely degrades and induces natural scar tissue formation, resulting in permanent tubal occlusion without the need for anesthesia, incisions, or recovery time. The technology addresses a significant unmet need in women’s reproductive health by offering a more convenient and affordable option compared to surgical sterilization.

The newly granted patents include U.S. Patent No. 12,606,719 and patents in Japan (JP Nos. 7,379,157 and 7,594,647), South Korea (KR No. 10-2713236), Brazil (BR No. 1120190157140), Hong Kong (HK No. HK40018048), India (IN No. 430804), and multiple European countries under the European Patent Office (EPO No. 3,579,890). The European patent extends to Belgium, Denmark, Germany, France, Ireland, Spain, Great Britain, Italy, Luxembourg, the Netherlands, Sweden, Turkey, and Switzerland.

These patents build upon Femasys’ existing intellectual property portfolio that covers the FemBloc delivery system, thereby strengthening the company’s competitive position in a highly regulated market with stringent clinical and regulatory requirements. FemBloc is currently approved for marketing in Europe, the UK, New Zealand, and select international markets, while remaining investigational in the United States.

Kathy Lee-Sepsick, Chief Executive Officer and Founder of Femasys, emphasized the significance of the new patents, stating, “Developing a truly new approach to permanent birth control requires overcoming significant scientific, technical and regulatory hurdles. These first issued patents covering the blended polymer extend protection for the FemBloc solution beyond the delivery system and further strengthen the intellectual property foundation supporting this differentiated approach.”

Femasys is advancing FemBloc through the ongoing U.S. pivotal FINALE trial (NCT05977751) as it seeks FDA approval. The company also focuses on commercializing its fertility portfolio, including FemaSeed® Intratubal Insemination and complementary diagnostic and sperm preparation products, in the U.S. and international markets.

FemBloc’s regulatory approvals in Europe, the UK, and New Zealand, obtained in 2025, have enabled commercialization through strategic partnerships in select international regions. The product’s clinical data demonstrate favorable safety profiles, encouraging effectiveness results, and high satisfaction among patients and practitioners.

Femasys’ expanding patent portfolio is a critical asset as the company works to bring FemBloc to women worldwide, protecting the innovation behind this transformative permanent birth control technology. Further information about FemBloc and Femasys’ product offerings is available at www.FemBloc.com.